Is Retatrutide More Effective Than Tirzepatide for Weight Loss?

Step 1: understand what each medicine is doing differently

Tirzepatide activates two receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). That dual action is what distinguishes it from semaglutide, which targets GLP-1 alone. You can read more about how tirzepatide works on our tirzepatide overview.

Retatrutide goes a step further by also activating the glucagon receptor. Glucagon normally raises blood sugar and drives the liver to burn stored fat, suppressing and modulating it simultaneously with the two incretin signals is the theoretical basis for the extra weight-loss effect seen in early data. It is sometimes called a triple agonist, or a GIP/GLP-1/glucagon receptor agonist. Whether that third pathway translates cleanly into real-world benefit at therapeutic doses, across a general population, with an acceptable safety profile, is exactly what phase 3 trials are designed to establish. The answer is not yet in.

There is a common assumption that a triple agonist must simply be better than a dual one in the same way that a more powerful engine is better. Pharmacology is rarely that tidy. More receptor targets can mean more interactions, unpredictable tolerability, and benefit profiles that suit some patients far more than others. The science here is genuinely promising, but promising is not the same as proven.

Step 2: read the phase 2 retatrutide data carefully

The phase 2 trial of retatrutide, published in the New England Journal of Medicine in 2023, randomised 338 adults with obesity or overweight and at least one weight-related condition. Participants at the highest dose (12 mg) lost around 24% of body weight over 48 weeks. That figure drew a great deal of attention, and rightly so.

But phase 2 trials are designed to find the right dose and check for safety signals, not to demonstrate efficacy at scale. The SURMOUNT-1 tirzepatide trial enrolled 2,539 participants over 72 weeks; the evidence base for retatrutide is, at this point, far smaller and shorter. Comparing a 24% figure from 338 people over 48 weeks with a ~20–21% figure from thousands of people over 72 weeks requires real caution. Trial designs, populations, duration and statistical approaches all affect the headline number. You can explore how tirzepatide's evidence base is constructed on our Mounjaro page.

Phase 3 retatrutide trials are recruiting or under way. Until those read out and pass regulatory scrutiny, the efficacy comparison remains genuinely open.

Step 3: weigh up what is actually available, and why that is the practical question

Tirzepatide is licensed by the MHRA, recommended by NICE (TA1026, published December 2024), and available through regulated UK pharmacies right now. It has been assessed for safety and efficacy across a large clinical programme covering over 10,000 participants in the combined SURPASS and SURMOUNT trials. For UK adults with a BMI of 30 or above, or 27 or above with a weight-related condition, it represents the most effective treatment currently accessible. Our retatrutide versus Mounjaro page covers the licensing gap in more detail.

Retatrutide has no UK marketing authorisation, no NICE appraisal, and no regulated prescribing pathway in this country as of mid-2026. If you encounter sellers offering it, that is a serious concern. The MHRA has warned repeatedly about medicines sold outside the licensed supply chain, and prescription medicines supplied without clinical oversight carry real risk. Our page on mixing tirzepatide and retatrutide addresses questions about combining the two.

The cost picture is also worth considering: since retatrutide has no UK pricing or licensing framework, any cost comparison is speculative. Our retatrutide cost comparison page explains why published US research prices say very little about what UK patients would eventually pay.

Step 4: what this means for anyone making a treatment decision now

If you are researching retatrutide because you want the most effective option available, the honest answer is that tirzepatide is the strongest-evidenced, licensed treatment you can receive in the UK today. Whether retatrutide will eventually prove superior in phase 3 conditions, and whether regulators will approve it, is a question the next few years will answer.

A question our prescribers hear regularly is whether waiting for the next medicine makes sense. For most people carrying excess weight, the evidence strongly supports treating now rather than waiting for a hypothetical future approval that could be two to four years away. Weight-related health conditions do not wait. Our weight-loss treatment overview sets out the options currently available, and if you want a broader look at the effectiveness evidence for oral alternatives, our page on oral tirzepatide's effectiveness covers that ground too.

Suitability for any weight-management medicine depends on your full health picture, not just your BMI. A prescriber can only assess that in a proper consultation. If you would like to speak to our clinical team directly, start your free consultation and a GPhC-registered prescriber will review your case the same day.